Showing results (1271-1280 of 1,331) with videos related to

Sort By:
Pageof 134
HGG Advances|April 4, 2022
Somatic activating BRAF variants cause isolated lymphatic malformationsKaitlyn Zenner, Dana M Jensen, Victoria Dmyterko, et al.
Eye (London, England)|April 2, 2022
Longitudinal follow-up and outcome analysis in central serous chorioretinopathyNiroj Kumar Sahoo, Joshua Ong, Amrish Selvam, et al.
Journal of Medicinal Chemistry|February 17, 2018
( S)-2-Amino-3-(5-methyl-3-hydroxyisoxazol-4-yl)propanoic Acid (AMPA) and Kainate Receptor Ligands: Further Exploration of Bioisosteric Replacements and Structural and Biological InvestigationSimone Brogi, Margherita Brindisi, Stefania Butini, et al.
Breast Cancer Research : BCR|June 23, 2025
Combined prognostic impact of initial clinical stage and residual cancer burden after neoadjuvant systemic therapy in triple-negative and HER2-positive breast cancer: an analysis of the I-SPY2 randomized clinical trialRoberto A Leon-Ferre, K Dimitroff, C Yau, et al.
European Journal of Ophthalmology|October 3, 2024
Longitudinal structural changes in central serous chorioretinopathy: A multimodal imaging-based studyNiroj Kumar Sahoo, Joshua Ong, Amrish Selvam, et al.
BMJ Open Respiratory Research|December 31, 2021
Phase 2 trial design of BMS-986278, a lysophosphatidic acid receptor 1 (LPA1) antagonist, in patients with idiopathic pulmonary fibrosis (IPF) or progressive fibrotic interstitial lung disease (PF-ILD)Tamera J Corte, Lisa Lancaster, Jeffrey J Swigris, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|September 30, 2025
Van der Waals Template-Assisted Growth of Two-dimensional Sb2S3Sindhu Priya Giridhar, Irfan H Abidi, Jiawen Qiu, et al.
Nature Communications|October 4, 2024
Plekhg5 controls the unconventional secretion of Sod1 by presynaptic secretory autophagyAmy-Jayne Hutchings, Bita Hambrecht, Alexander Veh, et al.
Contemporary Clinical Trials|March 3, 2021
The FALCON program: Two phase 2b randomized, double-blind, placebo-controlled studies to assess the efficacy and safety of pegbelfermin in the treatment of patients with nonalcoholic steatohepatitis and bridging fibrosis or compensated cirrhosisManal F Abdelmalek, Edgar D Charles, Arun J Sanyal, et al.
Journal of Medicinal Chemistry|April 14, 2025
Efficacy and Toxicity Analysis of Selective BET Bromodomain Inhibitors in Models of Inflammatory Liver DiseaseLuke C Doskey, Cole R Scholtz, Nora R Vail, et al.
Pageof 134